Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients’ Upper and Lower Airways after IV-Antibiotic Therapy
Table 1
Clinical, microbiological, and serological characteristics of included patients and healthy controls.
Nominal variables
Absolute frequency
Cystic fibrosis patients
Gender (female)
17
10 (58.8%)
Nasal polyps
17
5 (29.4%)
History of sinonasal surgery
17
6 (35.3%)
Chronic rhinosinusitis
17
5 (29.4%)
Allergy
Aspergillus fumigatus
17
7 (41.2%)
House dust mite
3 (17.6%)
Grass pollen
2 (11.8%)
Pet hair (cat/dog)
2 (11.8%)/1 (5.9%)
ABPA
17
2 (11.8%)
Allergic rhinitis
17
2 (11.8%)
Diabetes mellitus
17
5 (29.4%)
IV-antibiotics
19
Tobramycin
18 (94.7%)
Ceftazidime
9 (47.4%)
Tazobactam/piperacillin
4 (21.1%)
Colistin
1 (5.3%)
Meropenem
6 (31.6%)
Therapy
Current azithromycin
17
12 (70.6%)
Current oral antibiotics
9 (52.9%)
Current inhalative antibiotics
16 (94.1%)
Recombinant DNAse
10 (58.8%)
Nasal topical bronchial steroids
8 (47.1%)
Current oral antimycotics
10 (58.8%)
Chronic colonization of UAW with*1
P. aeruginosa permanent
17
4 (23.5%)
P. aeruginosa intermittent
4 (23.5%)
Chronic colonization of LAW with*1
P. aeruginosa permanent
17
5 (29.4%)
P. aeruginosa intermittent
3 (17.6%)
UAW: detection of *2
12 (63.2%)
P. aeruginosa (mucoid)
19
6 (31.6%)
P. aeruginosa (nonmucoid)
4 (21.1%)
S. aureus
2 (10.5%)
MRSA
2 (10.5%)
LAW: detection of *2
16 (84.2%)
P. aeruginosa (mucoid)
19
9 (47.4)
P. aeruginosa (nonmucoid)
7 (36.8%)
S. aureus
3 (15.8%)
MRSA
2 (10.5%)
P. aeruginosa serum antibodies positive:
8 (50.0%)
Alkaline protease/borderline
16
8 (50%)/2 (12.5%)
Exotoxin A/borderline
9 (56.3%)/1 (6.3%)
Elastase/borderline
9 (56.3%)/1 (6.3%)
Healthy controls
Gender (female)
20
15 (75%)
Allergic rhinitis
1 (5%)
Allergy in general
4 (20%)
Postnasal drip
4 (20%)
History of ORL surgery
5 (25%)
Snore
3 (15%)
*1Permanent and intermittent colonization were stated using the criteria published by Lee et al. [34]. Chronic colonization is defined if 50% or more of cultures within the last year were found positive and intermittent if less than 50% of cultures within the last year were found positive. *2At inclusion date.
